WEBULL
News
ELTX
8.00
-3.90%
-0.33
Weekly Report: what happened at ELTX last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at ELTX last week (1117-1121)?
Weekly Report · 11/24 10:01
Elicio Therapeutics appoints Marc Wolfgang as CTO
TipRanks · 11/19 13:10
Elicio Therapeutics Names Marc J. Wolfgang as Chief Technology Officer
Reuters · 11/19 13:00
Press Release: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
Dow Jones · 11/19 13:00
H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)
TipRanks · 11/19 11:37
Weekly Report: what happened at ELTX last week (1110-1114)?
Weekly Report · 11/17 10:01
JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)
TipRanks · 11/14 13:16
Elicio Therapeutics files to sell 103,225 shares of common stock for holders
TipRanks · 11/13 22:10
Elicio Therapeutics GAAP EPS of -$0.60 misses by $0.12
Seeking Alpha · 11/13 22:08
Elicio Therapeutics Q3 net loss narrows, cash runway extended
Reuters · 11/13 21:10
Elicio Therapeutics Reports Lower-Than-Projected Disease Progressions in Phase 2 AMPLIFY-7P Trial
Reuters · 11/13 21:01
Press Release: Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Dow Jones · 11/13 21:01
Elicio Therapeutics: Q3 Earnings Snapshot
Barchart · 11/13 15:09
Weekly Report: what happened at ELTX last week (1103-1107)?
Weekly Report · 11/10 09:59
Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent
Seeking Alpha · 11/07 21:06
Elicio Therapeutics announces additional data from Phase 2 AMPLIFY-7P trial
TipRanks · 11/07 14:16
Elicio Therapeutics Publishes Data on ELI-002 Immune Response in mKRAS-Positive Cancer
Reuters · 11/07 14:13
Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors
Benzinga · 11/07 14:10
Elicio Therapeutics Reports Robust T Cell Responses in Phase 2 Trial of ELI-002 7P for KRAS-Mutant Pancreatic Cancer
Reuters · 11/07 14:00
More
Webull provides a variety of real-time ELTX stock news. You can receive the latest news about Elicio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.